{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:48:49Z","timestamp":1791676129729,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Scientific Research Projects of the Nanan District Health and Wellness Committee and Nanan District Science and Technology Bureau","award":["(2024-11)"],"award-info":[{"award-number":["(2024-11)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07159-x","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:32:55Z","timestamp":1783485175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single low-dose daratumumab enhances rituximab efficacy for sustained remission in treatment-refractory autoimmune cytopenias"],"prefix":"10.1007","volume":"105","author":[{"given":"Xiao","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7414-8433","authenticated-orcid":false,"given":"Yun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5522-3193","authenticated-orcid":false,"given":"Chun","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"7159_CR1","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.pcl.2013.08.009","volume":"60","author":"DT Teachey","year":"2013","unstructured":"Teachey DT, Lambert MP (2013) Diagnosis and management of autoimmune cytopenias in childhood. Pediatr Clin North Am 60:1489\u20131511. https:\/\/doi.org\/10.1016\/j.pcl.2013.08.009","journal-title":"Pediatr Clin North Am"},{"key":"7159_CR2","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1016\/S2352-3026(24)00144-3","volume":"11","author":"B Fattizzo","year":"2024","unstructured":"Fattizzo B, Marchetti M, Michel M et al (2024) Diagnosis and management of Evans syndrome in adults: first consensus recommendations. Lancet Haematol 11:e617\u2013e628. https:\/\/doi.org\/10.1016\/S2352-3026(24)00144-3","journal-title":"Lancet Haematol"},{"key":"7159_CR3","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1182\/bloodadvances.2021005610","volume":"5","author":"B Fattizzo","year":"2021","unstructured":"Fattizzo B, Michel M, Giannotta JA et al (2021) Evans syndrome in adults: an observational multicenter study. Blood Adv 5:5468\u20135478. https:\/\/doi.org\/10.1182\/bloodadvances.2021005610","journal-title":"Blood Adv"},{"key":"7159_CR4","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/bloodadvances.2024012585","volume":"8","author":"M Jalink","year":"2024","unstructured":"Jalink M, Jacobs CF, Khwaja J et al (2024) Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv 8:2622\u20132634. https:\/\/doi.org\/10.1182\/bloodadvances.2024012585","journal-title":"Blood Adv"},{"key":"7159_CR5","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.3324\/haematol.2021.279232","volume":"106","author":"E Crickx","year":"2021","unstructured":"Crickx E, Audia S, Robbins A et al (2021) Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia. Haematologica 106:3198\u20133201. https:\/\/doi.org\/10.3324\/haematol.2021.279232","journal-title":"Haematologica"},{"key":"7159_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3390\/jcm10010164","volume":"10","author":"JA Giannotta","year":"2021","unstructured":"Giannotta JA, Fattizzo B, Cavallaro F, Barcellini W (2021) Infectious Complications in Autoimmune Hemolytic Anemia. J Clin Med 10:164. https:\/\/doi.org\/10.3390\/jcm10010164","journal-title":"J Clin Med"},{"key":"7159_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/bjh.18398","volume":"200","author":"B Skopec","year":"2023","unstructured":"Skopec B, Bussel JB (2023) Should dexamethasone alone or in combination be the initial steroid for adult ITP: Still a relevant question. Br J Haematol 200:15\u201322. https:\/\/doi.org\/10.1111\/bjh.18398","journal-title":"Br J Haematol"},{"key":"7159_CR8","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1182\/blood.2021010968","volume":"137","author":"W Ghanima","year":"2021","unstructured":"Ghanima W, Gernsheimer T, Kuter DJ (2021) How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment. Blood 137:2736\u20132744. https:\/\/doi.org\/10.1182\/blood.2021010968","journal-title":"Blood"},{"key":"7159_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/bjh.18814","volume":"202","author":"MP Rai","year":"2023","unstructured":"Rai MP, Lee E-J, Bussel JB (2023) Maintenence rituximab following induction in autoimmune cytopenias. Br J Haematol 202:153\u2013158. https:\/\/doi.org\/10.1111\/bjh.18814","journal-title":"Br J Haematol"},{"key":"7159_CR10","doi-asserted-by":"publisher","unstructured":"Berentsen S, Fattizzo B, Barcellini W (2023) The choice of new treatments in autoimmune hemolytic anemia: how to pick from the basket? Front Immunol 14. https:\/\/doi.org\/10.3389\/fimmu.2023.1180509","DOI":"10.3389\/fimmu.2023.1180509"},{"key":"7159_CR11","doi-asserted-by":"publisher","first-page":"953716","DOI":"10.3389\/fimmu.2022.953716","volume":"13","author":"Y Lv","year":"2022","unstructured":"Lv Y, Shi H, Liu H, Zhou L (2022) Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently? Front Immunol 13:953716. https:\/\/doi.org\/10.3389\/fimmu.2022.953716","journal-title":"Front Immunol"},{"key":"7159_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5045\/br.2019.54.2.131","volume":"54","author":"JC Jaime-P\u00e9rez","year":"2019","unstructured":"Jaime-P\u00e9rez JC, Aguilar-Calder\u00f3n P, Salazar-Cavazos L et al (2019) Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico. Blood Res 54:131\u2013136. https:\/\/doi.org\/10.5045\/br.2019.54.2.131","journal-title":"Blood Res"},{"key":"7159_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/bjh.17655","volume":"194","author":"MJ Rieger","year":"2021","unstructured":"Rieger MJ, Stolz SM, Ludwig S et al (2021) Daratumumab in rituximab-refractory autoimmune haemolytic anaemia. Br J Haematol 194:931\u2013934. https:\/\/doi.org\/10.1111\/bjh.17655","journal-title":"Br J Haematol"},{"key":"7159_CR14","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3390\/cancers17091537","volume":"17","author":"T Don","year":"2025","unstructured":"Don T, Gadgeel M, Sava\u015fan S (2025) A Room for Long-Lived Plasma Cell Contribution in Immune Cytopenias? Cancers 17:1537. https:\/\/doi.org\/10.3390\/cancers17091537","journal-title":"Cancers"},{"key":"7159_CR15","doi-asserted-by":"publisher","unstructured":"Tsykunova G, Holme PA, Tran HTT et al (2025) Safety and efficacy of daratumumab in immune thrombocytopenia. Blood Adv 2025017279. https:\/\/doi.org\/10.1182\/bloodadvances.2025017279","DOI":"10.1182\/bloodadvances.2025017279"},{"key":"7159_CR16","doi-asserted-by":"publisher","first-page":"649441","DOI":"10.3389\/fimmu.2021.649441","volume":"12","author":"A Zaninoni","year":"2021","unstructured":"Zaninoni A, Giannotta JA, Gall\u00ec A et al (2021) The Immunomodulatory Effect and Clinical Efficacy of Daratumumab in a Patient With Cold Agglutinin Disease. Front Immunol 12:649441. https:\/\/doi.org\/10.3389\/fimmu.2021.649441","journal-title":"Front Immunol"},{"key":"7159_CR17","doi-asserted-by":"publisher","first-page":"102724","DOI":"10.1016\/j.bcmd.2023.102724","volume":"99","author":"I Vernava","year":"2023","unstructured":"Vernava I, Schmitt CA (2023) Daratumumab as a novel treatment option in refractory ITP. Blood Cells Mol Dis 99:102724. https:\/\/doi.org\/10.1016\/j.bcmd.2023.102724","journal-title":"Blood Cells Mol Dis"},{"key":"7159_CR18","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1182\/blood-2021-151410","volume":"138","author":"G Tsykunova","year":"2021","unstructured":"Tsykunova G, Holme PA, Tran HTT et al (2021) Daratumumab As a Treatment for Adult Immune Thrombocytopenia: A Phase II Study with Safety Run-in (the DART Study). Blood 138:2088. https:\/\/doi.org\/10.1182\/blood-2021-151410","journal-title":"Blood"},{"key":"7159_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S487895","volume":"14","author":"I Zoubi","year":"2025","unstructured":"Zoubi I, Warwar A, Perek S, Preis M (2025) Daratumumab and Romiplostim Combined Therapy for a Long-Standing Refractory Primary Immune Thrombocytopenia - Case Report. ImmunoTargets therapy 14:1\u20135. https:\/\/doi.org\/10.2147\/ITT.S487895","journal-title":"ImmunoTargets therapy"},{"key":"7159_CR20","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","volume":"390","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xu Y, Li H et al (2024) A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia. N Engl J Med 390:2178\u20132190. https:\/\/doi.org\/10.1056\/NEJMoa2400409","journal-title":"N Engl J Med"},{"issue":"14","key":"7159_CR21","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1056\/NEJMoa2513120","volume":"394","author":"DJ Kuter","year":"2026","unstructured":"Kuter DJ, Miura K, Patriarca A et al (2026) A Phase 2 Randomized Trial of Mezagitamab in Primary Immune Thrombocytopenia. N Engl J Med 394(14):1388\u20131398. https:\/\/doi.org\/10.1056\/NEJMoa2513120","journal-title":"N Engl J Med"},{"key":"7159_CR22","doi-asserted-by":"publisher","first-page":"E263","DOI":"10.1002\/ajh.27025","volume":"98","author":"J McGlothlin","year":"2023","unstructured":"McGlothlin J, Abeykoon J, Al-Hattab E et al (2023) Bortezomib and daratumumab in refractory autoimmune hemolytic anemia. Am J Hematol 98:E263\u2013E265. https:\/\/doi.org\/10.1002\/ajh.27025","journal-title":"Am J Hematol"},{"key":"7159_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41572-024-00566-2","volume":"10","author":"M Michel","year":"2024","unstructured":"Michel M, Crickx E, Fattizzo B, Barcellini W (2024) Autoimmune haemolytic anaemias. Nat Rev Dis Primer 10:82. https:\/\/doi.org\/10.1038\/s41572-024-00566-2","journal-title":"Nat Rev Dis Primer"},{"key":"7159_CR24","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/bjh.18582","volume":"200","author":"M Kuwana","year":"2023","unstructured":"Kuwana M, Ito T, Kowata S et al (2023) Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study. Br J Haematol 200:802\u2013811. https:\/\/doi.org\/10.1111\/bjh.18582","journal-title":"Br J Haematol"},{"key":"7159_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/ajh.27144","volume":"99","author":"DJ Kuter","year":"2024","unstructured":"Kuter DJ, Piatek C, R\u00f6th A et al (2024) Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD). Am J Hematol 99:79\u201387. https:\/\/doi.org\/10.1002\/ajh.27144","journal-title":"Am J Hematol"},{"key":"7159_CR26","doi-asserted-by":"publisher","first-page":"1215216","DOI":"10.3389\/fimmu.2023.1215216","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Murakhovskaya I (2023) Rituximab resistance in ITP and beyond. Front Immunol 14:1215216. https:\/\/doi.org\/10.3389\/fimmu.2023.1215216","journal-title":"Front Immunol"},{"key":"7159_CR27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MC et al (2022) Mechanisms of Resistance to Noncovalent Bruton\u2019s Tyrosine Kinase Inhibitors. N Engl J Med 386:735\u2013743. https:\/\/doi.org\/10.1056\/NEJMoa2114110","journal-title":"N Engl J Med"},{"key":"7159_CR28","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/blood.2022018665","volume":"141","author":"S Guillet","year":"2023","unstructured":"Guillet S, Crickx E, Azzaoui I et al (2023) Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study. Blood 141:2867\u20132877. https:\/\/doi.org\/10.1182\/blood.2022018665","journal-title":"Blood"},{"key":"7159_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bjh.19078","volume":"203","author":"H Al-Samkari","year":"2023","unstructured":"Al-Samkari H, Neufeld EJ (2023) Novel therapeutics and future directions for refractory immune thrombocytopenia. Br J Haematol 203:65\u201378. https:\/\/doi.org\/10.1111\/bjh.19078","journal-title":"Br J Haematol"},{"key":"7159_CR30","doi-asserted-by":"publisher","unstructured":"Verkleij CPM, Frerichs KA, Broekmans MEC et al (2023) NK cell phenotype is associated with response and resistance to daratumumab in relapsed\/refractory multiple myeloma. 7(5):e881. https:\/\/doi.org\/10.1097\/HS9.0000000000000881","DOI":"10.1097\/HS9.0000000000000881"},{"key":"7159_CR31","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/bjh.19752","volume":"205","author":"J Weisinger","year":"2024","unstructured":"Weisinger J, Bouzid R, Ranta D et al (2024) Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpura. Br J Haematol 205:1951\u20131958. https:\/\/doi.org\/10.1111\/bjh.19752","journal-title":"Br J Haematol"},{"key":"7159_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00277-022-05035-y","volume":"102","author":"T Str\u00fc\u00dfmann","year":"2023","unstructured":"Str\u00fc\u00dfmann T, Jung J, Heinz J et al (2023) Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab. Ann Hematol 102:245\u2013247. https:\/\/doi.org\/10.1007\/s00277-022-05035-y","journal-title":"Ann Hematol"},{"key":"7159_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/bjh.19553","volume":"205","author":"Y Hu","year":"2024","unstructured":"Hu Y, Wang Z, Ma J et al (2024) The early and rapid response to daratumumab in children with chronic refractory immune thrombocytopenia from a referral single centre of China. Br J Haematol 205:300\u2013305. https:\/\/doi.org\/10.1111\/bjh.19553","journal-title":"Br J Haematol"},{"key":"7159_CR34","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/s41590-022-01345-5","volume":"23","author":"X Liu","year":"2022","unstructured":"Liu X, Yao J, Zhao Y et al (2022) Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota. Nat Immunol 23:1564\u20131576. https:\/\/doi.org\/10.1038\/s41590-022-01345-5","journal-title":"Nat Immunol"},{"key":"7159_CR35","doi-asserted-by":"publisher","first-page":"e881","DOI":"10.1097\/HS9.0000000000000881","volume":"7","author":"CPM Verkleij","year":"2023","unstructured":"Verkleij CPM, Frerichs KA, Broekmans MEC et al (2023) NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed\/Refractory Multiple Myeloma. HemaSphere 7:e881. https:\/\/doi.org\/10.1097\/HS9.0000000000000881","journal-title":"HemaSphere"},{"key":"7159_CR36","doi-asserted-by":"publisher","first-page":"863177","DOI":"10.3389\/fimmu.2022.863177","volume":"13","author":"JR Blase","year":"2022","unstructured":"Blase JR, Frame D, Michniacki TF, Walkovich K (2022) Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies. Front Immunol 13:863177. https:\/\/doi.org\/10.3389\/fimmu.2022.863177","journal-title":"Front Immunol"},{"key":"7159_CR37","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40164-020-00163-5","volume":"9","author":"S-H Chao","year":"2020","unstructured":"Chao S-H, Chang Y-L, Yen J-C et al (2020) Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis. Exp Hematol Oncol 9:6. https:\/\/doi.org\/10.1186\/s40164-020-00163-5","journal-title":"Exp Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07159-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07159-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07159-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:04:18Z","timestamp":1791673458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07159-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7159"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07159-x","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was carried out using the opt-out method for the case series of our hospital. The study was approved by the Ethics Committee of the Second Affiliated Hospital of Chongqing Medical University and was conducted in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was waived by our Institutional Review Board because of the retrospective nature of our study.","order":1,"name":"Ethics","label":"Ethics approval and consent for participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have contributed to the preparation of this manuscript and have approved its submission for publication. The order of authors listed in the manuscript has been agreed upon by all authors.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"436"}}